patient access

Questions on CGRP

Real News on CGRP Access

May 22, 2018 / 0 Comments

Aimovig, the first CGRP inhibitor drug, was approved by the FDA on May 17, 2018. This is extremely exciting news, but there are a lot of questions swirling around as many of us are anxious to try this new medicine. For the most up-to-date information about Aimovig visit Aimovig.com. The site includes Frequently Asked Questions, information on how the drug works, safety information AND information about a co-pay assistance program and a two-month free trial program. Worried About Access To CGRP Inhibitors? Many patient groups are working to address anticipated access issues to this new medication, including how to get a prescription from your doctor and to how to get your insurance company to cover it. However, these questions won’t be answered overnight.  You are not alone and you deserve access to care that is appropriate for the disease you have. The information below may answer some of your immediate questions, guide…

Keep Reading...

My 2nd ICER Submission for CGRP Review

May 8, 2018 / 0 Comments

To find out more about ICER (Institute for Clinical & Economic Review) watch this video or check out the Patient Input Guide. This is my submission to ICER about the importance their review of new CGRP inhibitor drugs will have on my life and our entire community. -Katie ICER OPEN COMMENT PERIOD ON CGRP INHIBITORS FOR MIGRAINE I had my first migraine attack with aura at age five. My vision was obstructed by a sparkling crescent moon shape. Within 20 minutes it had disappeared. Next it felt like someone was pounding a nail into my skull, over and over again. My parents held me in their arms for hours as I screamed in pain. I became dehydrated from crying, only making the searing pain in my head worse. The daylight streaming in from the window felt like more daggers. After six hours of torture, I vomited until my stomach was…

Keep Reading...

Migraine Patient Input for ICER Report – My Submission

November 28, 2017 / 0 Comments

Introduction I wanted to share my response to the ICER patient input questions. I definitely went into a lot of detail. Please do not feel you need write a book. The questions that are the most important to focus on are #1, #2, #4, #5, & #7. It’s ok to leave questions blank. To learn more about the Migraine Patient Open Input period and how ICER’s review will impact access to new CGRP medications, visit https://www.headachemigraineforum.org/advocacy/ The ICER form can be found here: https://icer-review.org/patient-guide-to-open-input/ This is our chance to be heard! But the deadline is this Thurs, Nov 30th at 5pm EST! If you want to share your responses, let me know and I’d be happy to post them there! ____________________________________________________ On which ICER report are you providing input? Erenumab for Migraine Organization (if applicable): Patient Briefly describe your disease experience, including your diagnosis, treatments you’ve used, etc. Be as…

Keep Reading...
Katie Golden

Katie is a professional patient, writer for Migraine.com, US Pain Ambassador, patient advocate, speaker, and freelance writer.

Archives